Oncopeptides
1.39 SEK
+0.07 %
Less than 1K followers
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Oncopeptides
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 118.3 | 8.4 | 35.2 | 31.7 | 71.1 | ||
| growth-% | -92.9 % | 321.3 % | -10.1 % | 124.7 % | |||
| EBITDA | -739.4 | -1,591.3 | -1,420.9 | -349.4 | -253.5 | -283.5 | - |
| EBIT | -739.4 | -1,591.3 | -1,420.9 | -349.4 | -253.5 | -283.5 | -224.7 |
| Profit before taxes | -739.9 | -1,592.4 | -1,421.4 | -337.7 | -248.5 | -284.2 | -248.2 |
| Net income | -740.7 | -1,594.7 | -1,430.3 | -338.0 | -249.1 | -284.6 | -249.6 |
| EPS | -9.08 | -16.21 | -12.04 | -2.61 | -1.75 | -1.52 | -1.04 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -1,201.2 % | -4,178.8 % | -719.6 % | -895.7 % | |||
| EBIT-% | -1,201.2 % | -4,178.8 % | -719.6 % | -895.7 % | -315.9 % | ||
| ROE | -92.9 % | -276.4 % | -678.3 % | -114.8 % | -438.7 % | -524.2 % | 423.8 % |
| ROI | -74.6 % | -168.4 % | -325.5 % | -87.7 % | -104.5 % | -116.6 % | -185.1 % |